Berrak zihinler için yalın, zengin, bağımsız bir Türkçe dijital medya üyeliği.
Ücretsiz Kaydol →
lecanemab ile ilgili hikayeler
• Eisai and Biogen on Friday gained US approval for their Alzheimer's drug lecanemab, developed for patients in the earliest stages of the mind-wasting disease. The US Food and Drug Administration approved the drug —which will be sold under the brand Leqembi— via the Accelerated Approval pathway. The companies said on Saturday the Japanese drugmaker had also applied for full FDA approval of the drug. Eisai Zoom in: The drug belongs to a class of treatments ...Devamını Oku
09 Oca 2023
• Biogen shares surged more than 35% as the new Alzheimer’s drug it developed with Japan’s Eisai was hailed as an “unequivocal win” by analysts at a late-stage clinical trial, adding more than $10 billion to its market capitalization and putting it on track to erase all of its losses this year. Biogen The trial: Biogen and Eisai said their experimental drug, lecanemab, slowed the progress of the disease by 27% compared with a placebo, in a large trial of pati...Devamını Oku
29 Eyl 2022